H.C. Wainwright analyst Ed Arce maintained a Buy rating on Tetraphase (NASDAQ: TTPH) today and set a price target of $6. The company’s shares closed on Friday at $2.97, close to its 52-week low of $2.05.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 22.7% and a 41.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Avenue Therapeutics Inc.
Currently, the analyst consensus on Tetraphase is a Moderate Buy with an average price target of $6, representing a 102.0% upside. In a report issued on August 3, B.Riley FBR also reiterated a Buy rating on the stock with a $6 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.98 and a one-year low of $2.05. Currently, Tetraphase has an average volume of 700.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.
